Zacks: Analysts Anticipate Oramed Pharmaceuticals, Inc. (ORMP) Will Post Quarterly Sales of $610,000.00

Share on StockTwits

Wall Street brokerages expect that Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) will report sales of $610,000.00 for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Oramed Pharmaceuticals’ earnings, with estimates ranging from $600,000.00 to $620,000.00. Oramed Pharmaceuticals posted sales of $4.29 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 85.8%. The firm is scheduled to report its next quarterly earnings report on Wednesday, December 5th.

On average, analysts expect that Oramed Pharmaceuticals will report full-year sales of $2.43 million for the current year, with estimates ranging from $2.42 million to $2.45 million. For the next fiscal year, analysts expect that the company will post sales of $3.92 million per share, with estimates ranging from $2.50 million to $6.47 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research firms that that provide coverage for Oramed Pharmaceuticals.

Oramed Pharmaceuticals (NASDAQ:ORMP) last issued its earnings results on Thursday, July 12th. The biotechnology company reported ($0.30) EPS for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.03). Oramed Pharmaceuticals had a negative return on equity of 63.20% and a negative net margin of 204.00%. The company had revenue of $0.62 million during the quarter, compared to analysts’ expectations of $0.61 million.

A number of analysts have recently commented on the company. HC Wainwright set a $25.00 target price on Oramed Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, June 6th. ValuEngine upgraded Oramed Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, May 31st. Finally, B. Riley downgraded Oramed Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Monday, July 16th.

Institutional investors and hedge funds have recently modified their holdings of the company. Millennium Management LLC purchased a new stake in shares of Oramed Pharmaceuticals in the fourth quarter worth about $143,000. BlackRock Inc. purchased a new stake in shares of Oramed Pharmaceuticals in the second quarter worth about $209,000. Finally, Renaissance Technologies LLC boosted its stake in shares of Oramed Pharmaceuticals by 12.7% in the fourth quarter. Renaissance Technologies LLC now owns 93,500 shares of the biotechnology company’s stock worth $842,000 after buying an additional 10,500 shares during the last quarter. Hedge funds and other institutional investors own 1.59% of the company’s stock.

Shares of ORMP traded down $0.11 during mid-day trading on Friday, reaching $4.78. The company had a trading volume of 75,601 shares, compared to its average volume of 56,972. Oramed Pharmaceuticals has a 52-week low of $4.70 and a 52-week high of $11.34. The company has a market capitalization of $84.90 million, a price-to-earnings ratio of -6.05 and a beta of 0.39.

Oramed Pharmaceuticals Company Profile

Oramed Pharmaceuticals Inc engages in the research and development of pharmaceutical solutions for the use of orally ingestible capsules or pills for delivery of polypeptides. Its product portfolio includes ORMD-0801, an oral insulin capsule, which has completed Phase IIb clinical trials for the treatment of diabetes; and ORMD-0901, an analog for GLP-1 gastrointestinal hormone, which has completed Phase Ib clinical trials for the treatment of type 2 diabetes.

Featured Article: Outstanding Shares and The Effect on Share Price

Get a free copy of the Zacks research report on Oramed Pharmaceuticals (ORMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Oramed Pharmaceuticals (NASDAQ:ORMP)

Receive News & Ratings for Oramed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oramed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Recent Analysts’ Ratings Updates for Hellofresh
Recent Analysts’ Ratings Updates for Hellofresh
Fabrinet  Stock Rating Lowered by Needham & Company LLC
Fabrinet Stock Rating Lowered by Needham & Company LLC
Avanos Medical  Lifted to Outperform at Raymond James
Avanos Medical Lifted to Outperform at Raymond James
ASLAN PHARMACEUTICALS ADR REP 5’s  “Buy” Rating Reaffirmed at HC Wainwright
ASLAN PHARMACEUTICALS ADR REP 5’s “Buy” Rating Reaffirmed at HC Wainwright
Phore Hits Market Capitalization of $8.38 Million
Phore Hits Market Capitalization of $8.38 Million
Reviewing Timberland Bancorp  & First Connecticut Bancorp
Reviewing Timberland Bancorp & First Connecticut Bancorp


Leave a Reply

© 2006-2018 Ticker Report. Google+.